- Gepotidacin demonstrated 92.6% microbiological success in treating urogenital gonorrhea, showing potential as an oral treatment option.
- The EAGLE-1 trial enrolled 628 participants across six countries for the phase 3 study.
- Microbiological success was reported in 100% of participants with rectal gonorrhea treated with gepotidacin.
- Adverse events occurred in 74% of participants receiving gepotidacin, primarily gastrointestinal and mild to moderate in severity.
Source: The Lancet
